This trial is evaluating whether 2'-Fucosyllactose will improve 1 primary outcome and 1 secondary outcome in patients with Ileocolitis. Measurement will happen over the course of 20 weeks.
This trial requires 216 total participants across 2 different treatment groups
This trial involves 2 different treatments. 2'-Fucosyllactose is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
"While the lifetime risk of Crohn's disease remains very low, the lifetime risk of UC increases considerably over age 50. There appears to be some variation with ethnicity, gender, and region." - Anonymous Online Contributor
"It seems that when administered in a low dose (150 mg/kg/day) and given consistently over two years, FSL is safe for children and adolescents with IBD." - Anonymous Online Contributor
"Results from a recent paper gives some insights into IBDs based on the theory that they result from a combination of environmental, dietary and genetic factors." - Anonymous Online Contributor
"At present IBD therapies can delay and/or prevent disease recurrence, but are ineffective in arresting new lesions and preventing inflammation from occurring. A novel target for the treatment of inflammatory bowel disease in the future is the regulation of the mucosal immune response." - Anonymous Online Contributor
"Inflammatory bowel diseases (IBD) are debilitating diseases that affect the colon by making the colon inflamed. In recent years there has been an increasing number of reports of IBD in children and adolescents in the western world. Results from a recent clinical trial, pediatric patients and general physicians were asked what is IBD? answer: Most physicians mistakenly thought that IBD is a rare disease in childhood. Physicians' education about IBD and its symptoms is therefore greatly needed." - Anonymous Online Contributor
"There is no one treatment option for IBD that is used by all patients. The most recent data has focused on the use of 5-aminosalicylates. The use of these agents did not differ by patient characteristic, but patients with more extensive disease were less likely to be receiving 5-ASA at initiation of treatment. Data from older studies shows that more aggressive therapies can be effective. A trial of medical therapy alone can lead to cure in about 5% of patients with UC or CD. In UC, surgery and anti-TNF therapy can prevent endoscopic and clinical relapse in about a third of patients. In CD, anti TNF therapy is effective in preventing relapse in about 50% of patients." - Anonymous Online Contributor
"The rate of chronic disease occurrence in the United States is increasing. The proportion of the population affected is estimated to remain fairly stable between 2005 and 2015. Although these estimates were not based on IBD-related deaths or hospital utilization, they may serve as a reasonable estimate for estimating the burden of this chronic disorder in the U.S. population." - Anonymous Online Contributor
"There are many signs of autoimmune diseases such as arthritis, skin rashes and unexplained weight loss. There are many signs of inflammatory bowel diseases, including the gastrointestinal symptoms such as constipation and diarrhea. Anemia, hypothyroidism, and chronic fatigue may also be signs of inflammatory bowel disease." - Anonymous Online Contributor
"This case highlights the potential for an unexpected adverse reaction to a non-allergenic dietary fibre which, in the majority of individuals, does not cause an allergic reaction." - Anonymous Online Contributor
"Data from a recent study of the meta-analysis indicated that FL may improve quality of life for patients with IBD. Further large-scale trials are warranted to confirm the clinical benefits of FL for IBD patients." - Anonymous Online Contributor
"More than 45% of the patients with inflammatory bowel diseases treated with conventional therapies have a nonrespond. A substantial number never progress to endoscopy or respond. The use of specific biologic agents to prevent the onset and/or progression of inflammatory bowel disease can benefit these patients but requires larger, prospective studies to determine the indications." - Anonymous Online Contributor
"Dietary supplements may be an effective treatment for patients with IBD who have significant symptoms. However, research is needed before these supplements can be used in clinical practice." - Anonymous Online Contributor